United States - English - NLM (National Library of Medicine)

ulai health llc - ferrous sulfate (unii: 39r4tan1vt) (ferrous cation - unii:gw89581owr) -

United States - English - NLM (National Library of Medicine)

ulai health llc - ferrous sulfate (unii: 39r4tan1vt) (ferrous cation - unii:gw89581owr) -

United States - English - NLM (National Library of Medicine)

ulai health llc - calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb) -

United States - English - NLM (National Library of Medicine)

ulai health llc - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb) -

Singapore - English - HSA (Health Sciences Authority)

organon singapore pte. ltd. - montelukast sodium 4.160mg eqv montelukast - granule - 4 mg/packet - montelukast sodium 4.160mg eqv montelukast 4 mg/packet

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

organon malaysia sdn. bhd. - montelukast sodium -

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 4 mg - singulair® is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. singulair is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 15 years of age and older. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. hypersensitivity to any component of this product. pregnancy category b: there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, singulair should be used during pregnancy only if clearly needed. teratogenic effect: no teratogenicity was observed in rats and rabbits at doses approximately 100 and 110 times, respectively, the maximum recommended daily oral dose in adults based on aucs [see nonclinical toxicology (13.2)] . during worldwide marketing experience, congenital limb

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - montelukast sodium, quantity: 4.16 mg (equivalent: montelukast, qty 4 mg) - tablet, chewable - excipient ingredients: aspartame; mannitol; iron oxide red; hyprolose; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; flavour - prophylaxis and treatment of chronic asthma in adults and children two years of age and over. symptomatic treatment of seasonal allergic rhinitis

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - montelukast sodium, quantity: 5.2 mg (equivalent: montelukast, qty 5 mg) - tablet, chewable - excipient ingredients: hyprolose; aspartame; mannitol; microcrystalline cellulose; croscarmellose sodium; iron oxide red; magnesium stearate; flavour - prophylaxis and treatment of chronic asthma in adults and children over two years. symptomatic treatment of seasonal allergic rhinitis

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - montelukast sodium, quantity: 10.4 mg (equivalent: montelukast, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; iron oxide yellow; titanium dioxide; carnauba wax; hypromellose; iron oxide red; lactose monohydrate; hyprolose; magnesium stearate - prophylaxis and treatment of chronic asthma in adults and children over two years. symptomatic treatment of seasonal allergic rhinitis